Only one person developed HIV infection in year-long extensions of two PURPOSE trials.
MedPage Today news story
Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for PrEP, according to twin open-label extensions.
There were no new HIV cases in the PURPOSE 1 52-week open-label extension among adolescent girls and young women in South Africa and Uganda. That extension included 2,136 patients who remained on lenacapavir after the trial’s randomized blinded phase ended, and 2,496 patients who switched at the extension’s start to lenacapavir from either daily oral emtricitabine and tenofovir alafenamide (Descovy) or emtricitabine and tenofovir disoproxil fumarate (Truvada).
The PURPOSE 2 52-week open-label extension saw only one new HIV infection among the cisgender men and transgender or gender-nonbinary persons who continued treatment. That new case was among the 1,587 patients who remained on lenacapavir; there were no new HIV cases among the 827 patients who switched from daily oral PrEP to lenacapavir.
Read the full news story here.
/free registration is required/
View all MedPage Today reports from AIDS 2026
Source : MedPage Today
Related HIV and Co-Infections News
-
[AIDS 2026] Managed Healthcare Executive: Community-led chemsex harm reduction programs boost HIV retention in South Africa, other countries
-
Results of the CAPRISA 012c clinical trial of a combination of two bnAbs to prevent HIV infection in young women in southern Africa announced at AIDS 2026
-
[AIDS 2026] aidsmap: Promise of monthly oral pill sparks renewed interest in post-exposure prophylaxis (PEP)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.